LD-110

• Description :

  LD-110 is a highly efficient and effective PROTAC degrader targeting LSD1 (DC50 = 0.44 μM) . LD-110 promotes LSD1 degradation and increases the level of H3K4 dimethylation in a ubiquitin-proteasome-dependent manner. LD-110 inhibits the growth and survival of multiple esophagus squamous cancer cell (ESCC) lines by inducing apoptosis. LD-110 can be used for the study of esophagus squamous cancer. Red: LSD1 ligand (HY-178826) ; Blue: E3 ligase CRBN ligand (HY-14658) ; Black: Linker (HY-N2578) [1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; Histone Demethylase; PROTACs

• Related Pathways :

  Apoptosis; Epigenetics; PROTAC

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Smiles :

  O=C(NCCCCNC1=CC2=C(C(N(C(CC3)C(NC3=O)=O)C2=O)=O)C=C1)C4=CC=C(C5=NC=C(OCC6CCNCC6)C=C5C7=CC=C(C#N)C=C7)C=C4

• Molecular Formula :

  C42H41N7O6

• Molecular Weight :

  739.82

• References & Citations :

  [1]Zhuo J, et al. Discovery of LD-110 as an Effective LSD1 PROTAC Degrader for the Treatment of Esophagus Squamous Cancer. J Med Chem. 2025 Oct 23;68 (20) :21860-21877.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported